loading  Checking for direct PDF access through Ovid


To the Editor:
We appreciate the eloquent Letter to the Editor written by Rahmani et al entitled “Neurodevelopmental Sequelae After anti-VEGF treatment for Retinopathy of Prematurity: The Jury is Still Out,” which was written as an addendum to our Editorial and in response to two flawed recently published articles by Lien et al1 and Morin et al.2 Rahmani et al highlight the concerns and limitations of these reports that provide a biased representation of the neurodevelopmental sequelae in infants who seemed to have greater associated morbidity at baseline. Although we cannot draw conclusions regarding the long-term safety of bevacizumab use in pregnancy or in newborns until sufficiently powered, adequately controlled, prospective studies are completed, we do thank Rahmani et al for their valuable contribution to this ongoing debate, and we look forward to the results of the ongoing RAINBOW trial.
    loading  Loading Related Articles